slider-main.png

Ovoca Bio plc’s goal is to bring value to its Shareholders through selective investment in pharmaceutical and biotechnology development opportunities. 
In 2018 Ovoca Bio made its first investment in Ivix Ltd with its highly promising clinical stage asset. Ivix Ltd is developing a new proprietary drug for female sexual dysfunction, an area of significant unmet medical need. The magnitude of demand for treatments for female sexual dysfunction has only recently been recognized; it has the potential to become a substantial pharmaceutical market. At present, there are only a few options available for treating female sexual dysfunction, all with significant shortcomings. The observed efficacy and safety profile of Ivix’ drug candidate suggests it is capable of becoming a market leader in this therapeutic area. 

Libicore_banner.jpg

News

April 15, 2019

Ovoca Presents at BIO-Europe Spring® 2019, Vienna

More...
March 29, 2019

Ovoca / Ivix have updated Libicore product presentation. New version is now available on site.

More...
March 29, 2019

Grant of Share Options

More...